05 April 2024
05 April 2024
The director of BARDA’s medical countermeasures programs, Robert Johnson, PhD, talks about what the agency is planning to invest in the future.
Caris is entitled to receive $1.4bn in potential milestone payments, apart from sales-based tiered royalties, from Merck.
The treatment is indicated for complicated urinary tract infections, certain pneumonia types acquired during hospital stays, and bacteraemia.
Addex has also sold its preclinical neurological assets and drug discovery platform to Neurosterix for $5.5m and a 20% equity.
Incannex anticipates a smooth cash runway as it prepares for a Phase IIb IND submission for generalised anxiety disorder.
Lonza will produce the drug at its facility in Portsmouth, US.
The vaccines will be developed using Touchlight’s doggybone DNA technology, which speeds up the manufacturing process.
MiNA Therapeutics is entitled to receive upfront and development-based milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
